Natural Matrix Protein™ (NMP™) in Interbody Lumbar Fusion

NCT05972616 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2025-10-14

No results posted yet for this study

Summary

The objective of this study is to evaluate the performance of Induce Biologics NMP™ when used to promote interbody fusion for degenerative disease of the lumbar spine.

Conditions

  • Degenerative Disc Disease

Interventions

BIOLOGICAL

Natural Matrix Protein (NMP)

human bone allograft

Sponsors & Collaborators

  • Induce Biologics USA Inc.

    lead INDUSTRY

Principal Investigators

  • Pierce Nunley, MD · Spine Institute of Louisiana

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-02-21
Completion
2024-02-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05972616 on ClinicalTrials.gov